Panacea Biotec Ltd

Panacea Biotec Ltd Share Price Today: Live Updates & Key Insights

Get insights on Panacea Biotec Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Panacea Biotec Ltd Share Price Chart

Panacea Biotec Ltd Fundamentals

Traded Volume: 2,83,451

Market Cap(Cr): 2,114

Avg Traded Price 347.53

1 Year return -16.63%

Upper Circuit 356.6

Lower Circuit 341.6

P/E TTM -292.00

P/B Ratio -1.00

Traded Value(Cr) 978.33

EPS TTM -1.182

Book value -1.182

Dividend 0.00%

Panacea Biotec Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Panacea Biotec Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Panacea Biotec Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -14.69%

1M -20.54%

3M -16.11%

1Y -16.63%

YTD -18.86%

Panacea Biotec Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Panacea Biotec Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 2.55L

Day Before Yesterday 1.54L

1W Avg 1.53L

1M Avg 90068.29

3M Avg 1.69L

Panacea Biotec Ltd Technical Details

Panacea Biotec Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 339

Support 2 333

Support 3 324

Pivot Point : 348

Resistance 1 354

Resistance 2 363

Resistance 3 369

Panacea Biotec Ltd Corporate Actions

Panacea Biotec Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Panacea Biotec Ltd’s capital allocation strategies.

All

Ex-Date 19-Sep-2011 Type D Description 0.75/share@75.00% Record Date - Ratio 75.00

Ex-Date 16-Sep-2010 Type D Description 0.25/share@25.00% Record Date - Ratio 25.00

Ex-Date 19-Sep-2008 Type D Description 1.00/share@100.00% Record Date - Ratio 100.00

Ex-Date 21-Sep-2007 Type D Description 1.00/share@100.00% Record Date - Ratio 100.00

Dividends

Announcement Date 19-Sep-2011 Ex Dividend Date 19-Sep-2011 Dividend(%) 75

Announcement Date 16-Sep-2010 Ex Dividend Date 16-Sep-2010 Dividend(%) 25

Announcement Date 19-Sep-2008 Ex Dividend Date 19-Sep-2008 Dividend(%) 100

Announcement Date 21-Sep-2007 Ex Dividend Date 21-Sep-2007 Dividend(%) 100

Bonus

No Bonus has been declared by PANACEABIO

Splits

No Split has been declared by PANACEABIO

Others

Rights No Rights has been declared by PANACEABIO

Panacea Biotec Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Panacea Biotec Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Panacea Biotec Ltd's relative performance and valuation against major competitors.

Stock Name Biocon Ltd ₹396.85 (+0.43%) M. Cap (Cr) 530.57 1 Yr Return (%) +22.83% P/E (TTM) 109.28 PB Ratio 2.52

Stock Name Concord Biotech Ltd ₹1427.70 (-0.88%) M. Cap (Cr) 149.36 1 Yr Return (%) -28.30% P/E (TTM) 46.11 PB Ratio 8.24

Stock Name Advanced Enzyme Technologies Ltd ₹317.20 (-2.43%) M. Cap (Cr) 35.50 1 Yr Return (%) -14.48% P/E (TTM) 24.09 PB Ratio 2.65

Stock Name Panacea Biotec Ltd ₹345.15 (-3.21%) M. Cap (Cr) 21.14 1 Yr Return (%) -16.63% P/E (TTM) -292.00 PB Ratio 2.53

Stock Name Genesis IBRC India Ltd ₹158.30 (-1.98%) M. Cap (Cr) 2.06 1 Yr Return (%) NaN% P/E (TTM) -889.33 PB Ratio 24.12

Stock Name Alpa Laboratories Ltd ₹78.63 (-0.87%) M. Cap (Cr) 1.65 1 Yr Return (%) -28.91% P/E (TTM) 8.87 PB Ratio 0.97

Stock Name Bharat Immunological & Biological Corporation Ltd ₹20.20 (+0.40%) M. Cap (Cr) 0.87 1 Yr Return (%) -12.40% P/E (TTM) -4.72 PB Ratio 0.99

Panacea Biotec Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Panacea Biotec Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 3.94 Mar 2024 37.27 Mar 2023 -10.74 Mar 2022 -52.69 Mar 2021 38.27

PARTICULARS Investing Activities Mar 2025 -60.60 Mar 2024 -51.01 Mar 2023 2.41 Mar 2022 39.54 Mar 2021 -37.32

PARTICULARS Financing Activities Mar 2025 90.07 Mar 2024 12.82 Mar 2023 9.01 Mar 2022 9.83 Mar 2021 -7.20

PARTICULARS Net Cash Flow Mar 2025 33.41 Mar 2024 -0.92 Mar 2023 0.67 Mar 2022 -3.32 Mar 2021 -6.26

Panacea Biotec Ltd Shareholding Pattern

This shows the ownership breakdown of Panacea Biotec Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 72.48%

Public 24.65%

Other Institutions 1.8%

FII 1.06%

Mutual Funds null%

About Panacea Biotec Ltd

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Limited. The name of the Company was changed to the present Panacea Biotec Limited in 1993. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBL's Research & Development made a tie up with European MNC in the year 2001 and in 2002, an in-licensing agreement was made with Biotechnology Consortium of India for development & commercialization of Anthrax Vaccine. Also in the identical year of 2002, the company had commissioned Recombinant Vaccine production plant. During the year 2004, PBL made an in-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine, marketing joint venture with Chiron (now Novartis) Vaccines, UK and also made collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines. After a year in 2005, an in-licensing agreement was prepared with National Institute of Health, USA for Hair Growth Hormone. During the year 2006, ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh was goes live, which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture & market Measles Vaccine. Also in the same year of 2006, the company had inaugurated its Biopharmaceutical R&D Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008, made a collaboration to set-up 220 bed multi super-specialty hospital in NCR and also the company obtained a patent (Patent No. 7,371,412 B2) from US Patent & Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles in the identical year of 2008.During year 2008-09, Company's Joint Venture Company, Chiron Panacea Vaccines Pvt. Ltd. (CPV), set-up for marketing of innovativecombination and other vaccines in India has launched Hepatitis A vaccine HAVpur, in collaboration with Berna Biotech Ltd., Switzerland and the Company's Injectable Polio Vaccine PolProtecand monohib Vaccine (novoHib) in the Indian market.During the year 2008-09, the Company's associate firm, viz. M/s Lakshmi & The Manager, in which the Company had invested Rs.40 million (40% share), was taken over by a newly formed company, Lakshmi & Manager Holdings Limited. As a result of takeover ofthe said firm, the Company has been allotted Equity Shares for an amount of Rs.41 .3 million in the said company.The Company had launched generic product Tacrolimus in Germany in 2011 under the brand 'Tacpan' through Company's indirect wholly owned subsidiary company Panacea Biotec Germany GmbH (PBGG).In 2013, Company's 50:50 joint venture Adveta Power Pvt. Ltd with its associate PanEra Biotec Pvt. Ltd, incorporated to generate and distribute power or any other energy from conventional / non-conventional energy sources on a commercial basis. During the year 2013-14, the Company disposed of entire shareholding in its erstwhile WOS, Lakshmi & Manager Holdings Ltd. (LMH). Post such disposal, LMH and its WOS Trinidhi Finance Pvt. Ltd. and subsidiary Best General Insurance Company Ltd. ceased to be the subsidiaries of the Company w.e.f. 25 January, 2014. During the year 2015, the Company launched new products in various therapeutic categories including: Glizid M V ( Voglibose, Gliclaz ide & Metformin Hydrochloride)- Anti-diabetic; Calcom Plus (Coral Calcium, Vitamin D3 & Vitamin K2-7)- Orthopedic segment and RF Willgo (Paracetamol and Aceclofenac)- Pain management and To Plus (Paracetamol etc.) -Anti-cold. During 2016, Company introduced India's first indigenously developed high quality Oncology product, CABAPAN (Cabazitaxel) Injection, for treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC). Further, it introduced indigenously anti-diabetic drug, TENEPAN (Teneligliptin), for treatment of Type 2 Diabetes Mellitus (T2DM). In December 2016, it launched world's first fully liquid tetravalent vaccine, Easyfour-TT for active primary immunization and booster dose against Diphtheria, Tetanus, Pertussis (DTwP) and Haemophilus Influenza Type B (Hib).In March, 2017, it launched first liquid whole cell pertussis (wP) based Hexavalent Combination vaccine, EasySixTM. The Company had one subsidiary, viz. NewRise Healthcare Private Limited, which consequently ceased to be subsidiary of the Company effective from April 21, 2017.The Board of Directors of the Company had, at its meeting held on May 30, 2019 approved the Scheme of Arrangement between the Company and Ravinder Heights Limited (RVHL) and their respective shareholders and creditors for demerger of real estate business of the Company comprising of Radhika Heights Limited along with its step down subsidiaries and two real estate properties, into RVHL, which was approved from April 01, 2019 and the Scheme became effective from September 10, 2020.During the current year 2020, Radhika Heights Limited (RHL) along with its step down subsidiaries and two real estate properties, were demerged into RVHL and RHL and its subsidiaries have ceased to be the subsidiary of the Company w.e.f. September 10, 2020.During the FY 2019-20, the Company transferred its pharmaceutical formulations business including pharmaceutical formulations facility at Baddi and related research & development and natural products extraction activities at Lalru, to its wholly owned subsidiaryviz. Panacea Biotec Pharma Limited (PBPL) by way of slump sale on going concern basis, which completed with effect from February 1, 2020. As on March 31, 2021, Panacea Biotec Pharma Limited (PBPL ) became a material subsidiary of Company. The Company and PBPL entered into definitive agreements on February 28, 2022 for sale of Pharmaceutical Formulations Brandsof PBPL in India and Nepal to Mankind Pharma Limited at an aggregate consideration of Rs.18,720 million. As part of this arrangement, Mankind retained PBPL's well-trained sales and marketing team engaged in the pharmaceutical formulations business and saidtransaction was completed on March 3, 2022.During the year 2024, Company launched world's first fully liquid wP-IPV based Pentavalent Vaccine, EasyFourPol@. Company's wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL) launched the nanotechnology-based generic product, Paclitaxel protein bound in human albumin particles. The Phase III clinical trial for DengiAllr in adults, was initiated in August 2024.Valgapan (Valganciclovir) launched in Germany in FY 2025. Company scaled ChilRunr brands to over 10,000 retail outlets in India in FY 2025.

Chairman & Managing Director

Rajesh Jain

Registered office Ambala-Chandigarh Highway, null, Lalru, Punjab, 140501

FAX :91-1762-505900

Background

Incorporation Year 1984

Face Value ₹1.00

Market Lot 1

Panacea Biotec Ltd Latest News

VIEW MORE NEWS

FAQs on Panacea Biotec Ltd